Intensity Therapeutics targets strategic partnerships to accelerate INT230-6 development

Intensity Therapeutics, Inc.

Intensity Therapeutics, Inc.

INTS

0.00
  • Intensity Therapeutics will resume enrollment in the INVINCIBLE-4 presurgical TNBC study in Q3 2026 in Switzerland and France.
  • Enrollment will restart in the Phase 3 INVINCIBLE-3 soft tissue sarcoma trial at a limited number of U.S. sites.
  • Strategic partnering push will continue, targeting collaborations to expand INT230-6 across indications, geographies, disease stages, treatment settings.
  • Capital plan centers on a $60 million at-the-market facility to fund operations while preserving flexibility for potential deals.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Intensity Therapeutics Inc. published the original content used to generate this news brief on July 01, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.